Search research articles
Contact Us
Filters
Showing results (41-50 of 129) with videos related to
Page
of 13
Sort By:
The Lancet. Oncology
|
July 3, 2020
A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic
Crescens Tiu, Rajiv Shinde, Christina Yap, et al.
Journal of Hematology & Oncology
|
July 3, 2025
Treatment-related adverse events of antibody drug-conjugates in clinical trials
Harold Nathan Tan, Marta Ascanio Morcillo, Juanita Lopez, et al.
Oncotarget
|
January 27, 2018
Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models
Anne-Christine Wong Te Fong, Parames Thavasu, Sladjana Gagrica, et al.
Journal of Proteomics
|
July 22, 2023
Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines
Rachel Lau, Lu Yu, Theodoros I Roumeliotis, et al.
Journal of Proteomics
|
September 7, 2024
Corrigendum to "Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines" [Journal of Proteomics (2023) Volume 288, Article number 104973]
Rachel Lau, Lu Yu, Theodoros I Roumeliotis, et al.
British Journal of Cancer
|
October 16, 2018
Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre
Brent O'Carrigan, Joline Si Jing Lim, Awais Jalil, et al.
Oncology
|
October 12, 2011
Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials
Montserrat Blanco Codesido, Andre Tesainer Brunetto, Sophia Frentzas, et al.
Investigational New Drugs
|
August 5, 2010
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
Simon Pacey, Martin Gore, David Chao, et al.
Plos One
|
October 6, 2017
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments
Anna Minchom, Parames Thavasu, Zai Ahmad, et al.
Cancer Reports (Hoboken, N.J.)
|
June 26, 2024
A single-centre study evaluating a geriatric screening tool in oncology phase I trial patients
Mary Van Zyl, Anne Barell, Bridget Cooley, et al.
Page
of 13
Search research articles
Search
Showing results (41-50 of 129) with videos related to
Sort By:
Page
of 13
The Lancet. Oncology
|
July 3, 2020
A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic
Crescens Tiu, Rajiv Shinde, Christina Yap, et al.
Journal of Hematology & Oncology
|
July 3, 2025
Treatment-related adverse events of antibody drug-conjugates in clinical trials
Harold Nathan Tan, Marta Ascanio Morcillo, Juanita Lopez, et al.
Oncotarget
|
January 27, 2018
Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models
Anne-Christine Wong Te Fong, Parames Thavasu, Sladjana Gagrica, et al.
Journal of Proteomics
|
July 22, 2023
Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines
Rachel Lau, Lu Yu, Theodoros I Roumeliotis, et al.
Journal of Proteomics
|
September 7, 2024
Corrigendum to "Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines" [Journal of Proteomics (2023) Volume 288, Article number 104973]
Rachel Lau, Lu Yu, Theodoros I Roumeliotis, et al.
British Journal of Cancer
|
October 16, 2018
Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre
Brent O'Carrigan, Joline Si Jing Lim, Awais Jalil, et al.
Oncology
|
October 12, 2011
Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials
Montserrat Blanco Codesido, Andre Tesainer Brunetto, Sophia Frentzas, et al.
Investigational New Drugs
|
August 5, 2010
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
Simon Pacey, Martin Gore, David Chao, et al.
Plos One
|
October 6, 2017
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments
Anna Minchom, Parames Thavasu, Zai Ahmad, et al.
Cancer Reports (Hoboken, N.J.)
|
June 26, 2024
A single-centre study evaluating a geriatric screening tool in oncology phase I trial patients
Mary Van Zyl, Anne Barell, Bridget Cooley, et al.
Page
of 13